

Supplementary Online Content

Okiyama N, Yamaguchi Y, Koder M, et al. Distinct histopathologic patterns of finger eruptions in dermatomyositis based on myositis-specific autoantibody profiles. *JAMA Dermatol*. Published online July 10, 2019. doi:10.1001/jamadermatol.2019.1668

eTable. Clinical characteristics and histopathological classifications in the analyzed cases

eFigure. Histopathologic classification of skin eruptions in myositis-specific autoantibody-associated groups


This supplementary material has been provided by the authors to give readers additional information about their work.

Supplementary Table 1. Clinical characteristics and histopathological classifications in the analyzed cases.

Autoantigen for Myositis-specific autoantibody	Sex	Age	Site of finger skin biopsy	Myositis	Interstitial lung disease	Malignancy	Interface dermatitis	Psoriasiform dermatitis	Exematomous reaction	Vascular injury
ARS	M	31	Side	+	None	None				+
ARS	M	41	Side	+	Chronic	None		+		+
ARS	M	43	Side	+	Chronic	None	+	+	+	
ARS	M	46	Rear	+	None	None	+	+	+	
ARS	M	47	Rear	+	Chronic	None	+	+		
ARS	M	48	Side	None	Chronic	None	+	+	+	
ARS	M	54	Rear	+	None	None	+	+	+	
ARS	M	54	Rear	+	Chronic	None				
ARS	M	59	Side	+	Chronic	None	+	+		
ARS	M	62	Side	None	Chronic	None			+	+
ARS	M	65	Side	None	Chronic	None	+	+	+	+
ARS	F	33	Side	+	Chronic	Uterine cancer	+	+	+	+
ARS	F	45	Side	+	Chronic	None	+	+	+	+
ARS	F	46	Side	+	None	None				+
ARS	F	48	Side	None	Chronic	None	+	+	+	
ARS	F	48	Side	+	Chronic	None	+		+	+
ARS	F	49	Side	+	Chronic	None	+		+	
AR	F	54	Rear	+	Chronic	None	+	+	+	+
ARS	F	56	Side	+	Chronic	None		+	+	
ARS	F	58	Rear	None	None	Ovarian cancer				
ARS	F	59	Rear	+	Chronic	None	+			
ARS	F	60	Rear	+	Chronic	Appendix cancer				+
ARS	F	61	Side	None	Chronic	Breast cancer		+		
ARS	F	62	Side	+	Chronic	Breast cancer	+		+	+
ARS	F	63	Rear	None	Chronic	Breast cancer				+
ARS	F	68	Rear	None	Chronic	None			+	
ARS	F	68	Rear	+	Chronic	None	+		+	
ARS	F	70	Rear	+	Chronic	None	+	+		
ARS	F	72	Rear	None	Chronic	None		+		+
ARS	F	75	Side	None	Chronic	None	+	+	+	
MDA5	M	49	Rear	+	Rapidly progressive	None	+			+
MDA5	M	57	Rear	None	Rapidly progressive	None				+
MDA5	M	65	Rear	+	Rapidly progressive	None	+			+
MDA5	M	66	Rear	+	Rapidly progressive	None	+			+
MDA5	M	78	Rear	None	Rapidly progressive	None				
MDA5	F	44	Rear	+	Rapidly progressive	None	+			+
MDA5	F	56	Rear	+	Rapidly progressive	None				+
MDA5	F	57	Rear	None	Rapidly progressive	None	+			+

MDA5	F	49	Rear	None	Rapidly progressive	None	+			+
MDA5	F	69	Rear	None	Rapidly progressive	None	+			+
MDA5	F	63	Flexor	None	Rapidly progressive	None	+			
MDA5	F	57	Rear	+	Rapidly progressive	None	+			+
MDA5	F	59	Rear	+	Rapidly progressive	None	+			+
MDA5	F	62	Rear	None	Rapidly progressive	None			+	
MDA5	F	44	Flexor	None	Rapidly progressive	None				+
MDA5	F	62	Rear	None	Rapidly progressive	None	+			+
MDA5	F	45	Rear	+	Rapidly progressive	None	+			+
MDA5	F	54	Rear	None	Rapidly progressive	None		+	+	
MDA5	F	16	Rear	+	Rapidly progressive	none			+	
TIF1γ	M	42	Rear	+	None	None	+			+
TIF1γ	M	62	Rear	+	None	None				
TIF1γ	M	63	Rear	+	None	Lung cancer	+			+
TIF1γ	M	69	Rear	+	None	Pharyngeal cancer	+			
TIF1γ	M	69	Rear	+	None	Lung cancer	+			+
TIF1γ	M	73	Rear	None	None	None	+			+
TIF1γ	M	75	Rear	None	None	Esophageal cancer				+
TIF1γ	M	76	Rear	+	None	Lung cancer	+		+	
TIF1γ	M	79	Rear	+	None	Lung cancer				
TIF1γ	F	34	Rear	None	None	None	+			+
TIF1γ	F	35	Rear	None	None	None	+			
TIF1γ	F	37	Rear	+	None	None				
TIF1γ	F	39	Rear	None	None	None	+			
TIF1γ	F	42	Rear	+	None	None				+
TIF1γ	F	47	Rear	+	None	Ovarian cancer, Breast cancer				+
TIF1γ	F	51	Rear	+	None	Breast cancer	+			
TIF1γ	F	54	Rear	+	None	Breast cancer	+			
TIF1γ	F	60	Flexor	+	None	Colon cancer				
TIF1γ	F	63	Rear	+	None	Gastric cancer	+			
TIF1γ	F	65	Rear	+	None	None				
TIF1γ	F	67	Rear	None	None	None				+
TIF1γ	F	69	Rear	+	None	Gastric cancer	+			+
TIF1γ	F	74	Rear	+	None	Breast cancer	+	+		
TIF1γ	F	83	Rear	+	None	None	+			+
TIF1γ	F	88	Flexor	None	None	None				

M, Male; F, Female



Supplementary Figure 1. Histopathological classification of skin eruptions in myositis-specific autoantibody-associated groups. Anti-ARS antibody-associated DM group is characterized by a mixture of psoriasiform dermatitis and eczematous reaction with interface dermatitis mainly presenting dyskeratotic cells, and absent epidermal expression of MxA. Vascular injury in the upper dermis and a whole epidermal expression of MxA are observed especially in anti-MDA5 antibody-associated DM group.